Logistics and transport main concern related to clinical trial supply chain: Survey Results

23 December 2020 (Last Updated December 23rd, 2020 10:15)

The pharmaceutical supply chains were disrupted due to the Covid-19 pandemic creating a shortage of raw materials and ancillary supplies required for clinical trials.

The pharmaceutical supply chains were disrupted due to the Covid-19 pandemic creating a shortage of raw materials and ancillary supplies required for clinical trials.

GlobalData has conducted a survey to assess the clinical trial supply chain concerns for companies without marketed drugs and companies with pipeline and marketed drugs in the first and third quarters.

Commercial supply chain concerns

Clinical trial supply chain concerns by company type

A majority of 26% of companies with pipeline and marketed drugs in Q1 opined that logistics and transport was the main concern, which increased to 41% in Q3, while 20% of companies without marketed drugs expressed similar concerns in Q1, although the percentage declined to 7% in Q3.

API chemical (small molecule) was the next major concern expressed by 22% of companies with pipeline and marketed drugs in Q1, which declined to 15% in Q3, while 16% of companies without marketed drugs expressed the same concern in Q1, which increased to 20% in Q3.

Approximately 16% of companies without marketed drugs in Q1 voted for API biologics including advanced therapeutics as the main concern, which increased to 20% in Q3, while this concern was relatively lower for companies with pipeline and marketed drugs at 8% in Q1 and 4% in Q3.

API biologics was listed as the clinical trial supply chain concern by 16% of companies without marketed drugs in Q1, which declined to 13% in Q3, while 14% of companies with pipeline and marketed drugs listed the same concern in Q1, which declined to 4% in Q3.

Non-API raw materials was voted by 16% of companies without marketed drugs as the main concern in Q1, although the concern declined to 7% in Q3, while 8% of companies with pipeline and marketed drugs had similar concerns in Q1, which increased to 13% in Q3.

API intermediates was voted as the next main concern by 9% of companies with pipeline and marketed drugs in Q1, which increased to 15% in Q3, while the same concern was listed by 4% of companies without marketed drugs in Q1, which rose greatly to 27% in Q3.

Approximately 9% of companies with pipeline and marketed drugs opined that clinical dose was the main concern in Q1, which declined to 7% in Q3, while the concern was expressed by 7% of companies without marketed drugs in both the quarters.

Clinical packaging was the next concern listed by 7% of companies without marketed drugs in Q1 and 5% of companies with pipeline and marketed drugs. This concern was not raised by either type of companies in the third quarter.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.